CollPlant Biotechnologies (CLGN)

CollPlant’s work spans several related markets. In regenerative medicine, its materials are used in BioInk products for 3D bioprinting research and development, including efforts connected to tissues and, over the longer term, organ manufacturing. In medical aesthetics, rhCollagen may be used as a foundational biomaterial for products intended to restore or support soft tissue. The company has also reported activity in areas such as wound healing and tendinopathy products, particularly in Europe.

Revenue is generated through a mix of collaborations, sales of BioInk for 3D bioprinting, sales of rhCollagen for aesthetic applications and commercial activity tied to certain medical products. The company operates across several geographic markets, including the United States, Canada, Europe, Israel and other regions, with the United States representing an important revenue contributor.

For investors, CLGN is a biotechnology and biomaterials stock rather than a traditional medical device company. Its distinguishing feature is the potential versatility of plant-produced human collagen, which can serve as a platform material across aesthetics, tissue repair and advanced bioprinting. Its prospects depend on partner execution, regulatory pathways, product adoption and the ability to scale specialized biomaterial production.